[Featured Stock] Ildong Pharmaceutical 'Levels Up' with New Obesity and Diabetes Drug Development... R&D Subsidiary Officially Launched

Ildong Pharmaceutical is showing strength. The news that its dedicated research and development (R&D) subsidiary YUNOVIA has officially launched appears to be influencing the stock price.

As of 2:52 PM on the 2nd, Ildong Pharmaceutical is trading at 16,310 KRW, up 5.84% from the previous day.

YUNOVIA continues business activities based on the R&D assets and new drug pipelines held by Ildong Pharmaceutical. It has secured 6 to 7 new drug pipelines in the fields of metabolic diseases, degenerative diseases, liver diseases, gastrointestinal diseases, and ophthalmic diseases. Additionally, by adding cancer, cardiovascular diseases, neuropsychiatric diseases, infectious diseases, and pulmonary/respiratory disease new drug research projects, platform technologies, and microbiome projects, it currently holds about 25 pipelines.

Development is focused on the metabolic disease new drug candidate 'ID110521156' targeting type 2 diabetes and obesity, and the Parkinson's disease treatment candidate 'ID119040338'. The company explained that the metabolic disease new drug candidate 'ID110521156', a GLP-1 receptor agonist targeting type 2 diabetes and obesity, and the A1·A2A receptor antagonist 'ID119040338', being developed as a treatment for Parkinson's disease, a degenerative disease, are attracting interest from numerous global companies.

A YUNOVIA official stated, "We will establish ourselves as an R&D specialized company with a sustainable virtuous cycle structure by leading with competitive and promising pipelines."

Dalmi Lee, a researcher at the Korea IR Association, explained, "For companies like Hanmi Pharmaceutical, Yuhan Corporation, and Chong Kun Dang, whose market capitalization exceeds trillions of won, R&D achievements have led to increases in corporate value through license-outs or positive clinical data outcomes."

She added, "Ildong Pharmaceutical's corporate value has not yet reflected expectations for R&D, so its valuation attractiveness is considered high. If results are produced for the most anticipated diabetes treatment candidate ID110521156, the corporate value will level up."

This content was produced with the assistance of AI translation services.